The mechanism of cell-mediated cytotoxicity. III. Protease-specific inhibitors preferentially block later events in cytotoxic T lymphocyte-mediated lysis than do inhibitors of methylation or thiol-reactive agents.
Highly active mouse cytotoxic T lymphocytes (CTL) generated in secondary mixed-lymphocyte responses were used to examine the manner in which adenosine derivatives, thiol-specific reagents, or protease-specific probes affected CTL-mediated lysis (CML). The adenosine deaminase inhibitor deoxycoformycin (dCF) enhanced inhibition by adenosine (AR) or by deoxyadenosine (AdR), but not by 7-deazaadenosine (tubercidin). L-Homocysteinethiolactone (L-Hcy) acted synergistically with AR, but not with AdR or tubercidin, to block CML. Thus, AR derivatives may act both by affecting cellular methylation reactions, as demonstrated by the synergism between AR and L-Hcy, and by inhibiting other events required for CML. Conditions were then established to determine whether these reagents preferentially affected either the Ca2+-independent initial stage of cytolysis or the subsequent Ca2+-dependent events. Methylation inhibitors blocked lysis most effectively if added before effector-target binding. Similarly, the nonpenetrating thiol-specific reagent quaternary ammonium monobromobimane (qBBr) was more inhibitory when added prior to the Ca2+-dependent stage. Protease inhibitors such as alpha-1-antichymotrypsin and protease substrates such as acetyltyrosine ethyl ester (ATEE) or tyrosine ethyl ester (TEE) also inhibited CML. But, in contrast to qBBr or methylation inhibitors, neither TEE nor ATEE was more effective when added prior to the initial effector-target interaction. Furthermore, TEE did not appreciably affect CTL binding to target cells at concentrations that nearly abrogated CML. Thus, the implicated protease step is unique in that it does not appear to participate in recognition or binding.
D000241:Adenosine / Q000494:pharmacology; D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology; D002918:Chymotrypsin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003070:Coformycin / Q000031:analogs & derivatives / Q000494:pharmacology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D003839:Deoxyadenosines / Q000494:pharmacology; D008745:Methylation; D051379:Mice; D008815:Mice, Inbred Strains; D015649:Pentostatin; D010447:Peptide Hydrolases / Q000378:metabolism*; D013438:Sulfhydryl Compounds / Q000378:metabolism*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D013997:Time Factors; D014443:Tyrosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000514:alpha 1-Antichymotrypsin
D001643:Bridged Bicyclo Compounds; D003839:Deoxyadenosines; D013438:Sulfhydryl Compounds; D000514:alpha 1-Antichymotrypsin; D003070:Coformycin; D015649:Pentostatin; D014443:Tyrosine; C007651:ethyl N-alpha-acetyl-tyrosinate; C025787:N-acetyltyrosine; D010447:Peptide Hydrolases; D002918:Chymotrypsin; D000241:Adenosine; D002118:Calcium; C028381:monobromobimane